Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-29 22:53:18 - browse：7819

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： How to fix the rural physician shortage in the U.S.

WSS

Obesity drugs seen as possible treatment for liver disease MASH

R1 RCM gets $5.8 billion buyout offer from private equity firm

In utero gene editing: an explainer

Alabama frozen embryo ruling has major implications for IVF clinics

In utero gene editing: an explainer

In search for therapies for solid tumors, companies turn to claudin

focus

Wikipedia

knowledge

How to save PrEP access — and even expand it

Alabama IVF ruling threatens families facing fatal genetic disease

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why palliative psychiatry is worth discussing

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Obesity now affects over 1 billion people worldwide, study finds

Medicare details structure of new drug price negotiation program

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Apple is now the first public company to be valued at $3 trillion

New documents shed light on MD Anderson Cancer Institute feud

knowledge

An inside look at PIPEs, biotech's buzzy new financing tool

Dario to buy mental health app maker Twill in cash and stock deal

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Why palliative psychiatry is worth discussing

Kenai launches with $82 million for Parkinson’s stem cell therapy

How to fix the rural physician shortage in the U.S.

leisure time

leisure time

focus

focus